Rogerio De Figueiredo
Adjunct Professor
Institute of Biomedicine
University of Turku
Areas of expertise
Cancer Immunobiology and Immunotherapy
Pharmacology and biochemistry with emphasis in drug discovery. Dr. Carlos Rogério Figueiredo is a Principal Investigator and Docent of Immunology at the University of Turku, with a focus on cancer immunology and resistance to immunotherapy. Rogerio did his PhD in Immunology & Microbiology in the Federal University of São Paulo, Brazil, in 2015. Postdoctoral Fellowships Rogerio did in translational oncology in the University of Liverpool and in Immuno-oncology in the University of Turku. His research explores the molecular mechanisms underlying immunosuppression, leading to cold tumor formation and poor responses to current immunotherapies. As the leader of the Medical Immuno-Oncology Research Group (MIORG), he conducts integrative multi-omic studies to identify novel biomarkers to advance prognostication tools and evaluate their functional roles in antitumor immune responses. This work supports evidence-based insights for rational immunotherapy innovation, with a primary focus on cutaneous and ocular melanoma models. Rogerio is the winner of Scandinavian Society for Immunology (SSI) Young Investigator Award year 2024.
Cancer Immunobiology and Immunotherapy
Pharmacology and biochemistry with emphasis in drug discovery. Dr. Carlos Rogério Figueiredo is a Principal Investigator and Docent of Immunology at the University of Turku, with a focus on cancer immunology and resistance to immunotherapy. Rogerio did his PhD in Immunology & Microbiology in the Federal University of São Paulo, Brazil, in 2015. Postdoctoral Fellowships Rogerio did in translational oncology in the University of Liverpool and in Immuno-oncology in the University of Turku. His research explores the molecular mechanisms underlying immunosuppression, leading to cold tumor formation and poor responses to current immunotherapies. As the leader of the Medical Immuno-Oncology Research Group (MIORG), he conducts integrative multi-omic studies to identify novel biomarkers to advance prognostication tools and evaluate their functional roles in antitumor immune responses. This work supports evidence-based insights for rational immunotherapy innovation, with a primary focus on cutaneous and ocular melanoma models. Rogerio is the winner of Scandinavian Society for Immunology (SSI) Young Investigator Award year 2024.
